Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

David Einhorn Discusses Sprint $S in a Nov 7 Investor Letter

David Einhorn, the manager of the activist hedge fund Greenlight Capital, has a tendency to make waves. Einhorn knows his stuff and he is happy to explain his reasoning, especially to his investors. On November 7, he issued an investors’ letter that explained his thoughts on the firm’s investments. In Einhorn’s investor letter, he discusses several stocks specifically.

David Einhorn

David Einhorn on Sprint

One of the stocks that Einhorn discussed in detail was Sprint (S):

Sprint (S) shares fell from $5.39 to $3.04 in the quarter. First the company announced a disappointing quarterly result, driven by increased phone subsidies in an effort to achieve its targeted level of customers. From there, management went into an investor relations meltdown, hosting an investor day where S presented a capex-driven funding requirement over the next two years that was greater than it had previously communicated, and at the same time failed to explain how S would fund the additional investment. The company even managed to bungle the October announcement that it would finally offer the iPhone. Management is on the verge of losing the confidence of the financial markets.

Why David Einhorn isn’t Selling Out Sprint

David Einhorn isn’t walking away from the company just yet. In the letter, he explained:
We believe the business opportunity and asset values remain sufficient to justify holding the shares, and we wouldn’t be surprised if shareholders begin to agitate for significant strategic change. Given the heavy need to invest, the S opportunity may be better pursued by a new owner with a lower cost of capital.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!